Celecoxib (SC 58635)

Name: Celecoxib (SC 58635)
Brand: Selleck Chemicals
SKU: S1261
Rating: 5 (68 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1261

68 publications

CAS No. 169590-42-5

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Selleck's Celecoxib (SC 58635) has been cited by 68 publications

J Immunother Cancer, 2021, 9(6)e002305

PubMed: 34168004 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(3)1194

PubMed: 33530480 ( click the link to review the publication )

J Clin Invest, 2020, 26;132417

PubMed: 32452837 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6299

PubMed: 33288764 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6339

PubMed: 33311482 ( click the link to review the publication )

Cell Death Differ, 2020, 20

PubMed: 32433558 ( click the link to review the publication )

Nanotoxicology, 2020, 14(2):162-180

PubMed: 31703536 ( click the link to review the publication )

Cells, 2020, 14;9(5):E1222

PubMed: 32423044 ( click the link to review the publication )

Aging (Albany NY), 2020, 12

PubMed: 33180744 ( click the link to review the publication )

Neoplasia, 2020, 22(11):576-589

PubMed: 32980776 ( click the link to review the publication )

J Inflamm Res, 2020, 13:1043-1055

PubMed: 33293848 ( click the link to review the publication )

J Clin Periodontol, 2020, 10.1111/jcpe.13283

PubMed: 32160330 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Brain Res, 2020, 20;1740:146846

PubMed: 32325074 ( click the link to review the publication )

AAPS PharmSciTech, 2020, 17;21(5):135

PubMed: 32419073 ( click the link to review the publication )

Biol Open, 2020, 9(11)bio053447

PubMed: 33148606 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):626

PubMed: 32796811 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):172

PubMed: 32139667 ( click the link to review the publication )

Osteoarthritis Cartilage, 2020, 28(4):502-515

PubMed: 32061965 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106206

PubMed: 32018066 ( click the link to review the publication )

EBioMedicine, 2019, 47:142-155

PubMed: 31492557 ( click the link to review the publication )

Cancer Lett, 2019, 440-441:116-125

PubMed: 30343113 ( click the link to review the publication )
Cell Death Dis, 2019, 10(6):397

PubMed: 31113934 ( click the link to review the publication )

Front Pharmacol, 2019, 10:836

PubMed: 31440159 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Front Pediatr, 2019, 7:228

PubMed: 31231624 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Viruses, 2019, 11(12)

PubMed: 31842327 ( click the link to review the publication )

Chin J Dent Res, 2019, 22(4):221-227

PubMed: 31859282 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Theranostics, 2018,

PubMed: 30083255 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

Oncol Lett, 2018, 16(4):4526-4536

PubMed: 30214587 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9425-9441

PubMed: 29507700 ( click the link to review the publication )

Mucosal Immunol, 2018, 11(6):1663-1673

PubMed: 30082707 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2657-2666

PubMed: 29048666 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )
Oncol Lett, 2017, 14(5):5959-5965

PubMed: 29113232 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245915 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51748-51757

PubMed: 28881683 ( click the link to review the publication )

Oncotarget, 2017, 8(46):80651-80665

PubMed: 29113333 ( click the link to review the publication )

Cell Rep, 2016, 16(12):3334-3347

PubMed: 27653694 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(19):28435-47

PubMed: 27078846 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 69:132-41

PubMed: 26510582 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	NF3pZ\|dHfW6ldHnvckBCe3OjeR?=	NWj5OlVOOC5zLUOwJO69VQ>?	NG\BNGo1QCCq		NWS3NYN4cW6mdXPld{BKS0GPLUGg[ZhxemW\|c3nvckBwdiCkb4ToJJBzd3SnaX6gZY5lKG2UTlGgcIV3\Wx?	M4nIZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUGzNVczLz5{NkWxN\|E4OjxxYU6=
H460	MmrKSpVv[3Srb36gRZN{[Xl?	MY[wMlEuOzBizszN	MXm0PEBp		MVrpcoR2[2W\|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjVzM{G3Nkc,OjZ3MUOxO\|I9N2F-
HKESC-2	MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjrRY4zOMLizszN	MV20POKhcMLi		MU\zbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-
CaES-17	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWCwfXBjOjEEoN88US=>	NVPNXVQ3PDkEoHlCpC=>		NEH0OVF{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW\|IH;mJI95[WyrcHzheIlvyqB?	M2PaRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEe0Olk{Lz5{NkS3OFY6OzxxYU6=
HKESC-2	NGPxRWRCeG:ydH;zbZMhSXO\|YYm=	MoTHNlDDqM7:TR?=	M{X0SVQ5yqCqwrC=		NX;adYtFemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	NXzYNW1IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0O\|Q3QTNpPkK2OFc1Pjl\|PD;hQi=>
CaES-17	MVPBdI9xfG:\|aYOgRZN{[Xl?	M131PFIxyqEQvF2=	NXjDZVZjPDkEoHlCpC=>		MkG1doVlfWOnczDvfIFtcXCuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MoLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2N{S2PVMoRjJ4NEe0Olk{RC:jPh?=
A549	Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVr6Wo1RPS1zNkCg{txO	Ml7mOFjDqGkEoB?=	M37XNWROW09?	NVT5PWJwUUN3ME2xOlMvPCEQvF2=	NFO3U2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS2OFY1Oyd-Mk[0OlQ3PDN:L3G+
HCC827	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYW1MVE3OCEQvF2=	MkKwOFjDqGkEoB?=	M1XxPWROW09?	NF2ycYJKSzVyPU[5MlIh\|ryP	MlTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2NkS2OFMoRjJ4NE[0OlQ{RC:jPh?=
A549	MlrHRZBweHSxc3nzJGF{e2G7	M17nV\|gxKML3TR?=	M4jCN\|Q5yqCqwrC=	MWPEUXNQ	MYDpcoR2[2W\|IHHwc5B1d3Orcx?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR4NE[0N{c,OjZ2NkS2OFM9N2F-
HCC827	M3WwSGFxd3C2b4Ppd{BCe3OjeR?=	NEDFVZM5OCEEtV2=	M2PiXlQ5yqCqwrC=	M3z1T2ROW09?	NUjWRpJzcW6mdXPld{BieG:ydH;zbZM>	Mn64QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2NkS2OFMoRjJ4NE[0OlQ{RC:jPh?=
SGC-7901/DDP	MoLDSpVv[3Srb36gRZN{[Xl?	NGXtPIMyOMLiwsXN	M1L4XVI1KGh?		MmrUbY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW\|c3nvci=>	M3TVeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEC3OlU{Lz5{NkSwO\|Y2OzxxYU6=
SGC-7901	M4PpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEfnWXAzPMLiaNMg		MVXJR\|UxRTFzNT6wPEDPxE1?	M3TWblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEC3OlU{Lz5{NkSwO\|Y2OzxxYU6=
SGC-7901/DDP	M2\4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1zEc\|I1yqCqwrC=		M4D3VmlEPTB;M{WuOFUh\|ryP	Mn;MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MEe2OVMoRjJ4NEC3OlU{RC:jPh?=
SGC-7901/DDP	NGnWSFRCeG:ydH;zbZMhSXO\|YYm=	Mn3JNVDDqML3TR?=	MmPnNlQhcA>?		NFPBc2pqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIIfpeIgh[2m\|cHzheIlv	M{ewZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEC3OlU{Lz5{NkSwO\|Y2OzxxYU6=
SGC-7901/DDP	M2qxfmZ2dmO2aX;uJGF{e2G7	NGHzbXgyOMLiwsXN	MlrFNlQhcA>?		NULEb\|BVcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4YhWC2pbInjc5Bzd3SnaX6geIhzd3WpaDDicI9kc2mwZzDFVFItKGGwZDDpcoFkfGm4YYTpcochWEuDIHHu[EBEWkWEwrC=	M2fhdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEC3OlU{Lz5{NkSwO\|Y2OzxxYU6=
SGC-7901/DDP	MXXGeY5kfGmxbjDBd5NigQ>?	NYC3O\|hkOTEEoNM1US=>	MorCNlQhcA>?		M1;DboNifXOnczDhJI1iemunZDDk[YNz\WG\|ZTDpckB1cGVibHX2[Ywhd2ZiQnPsMVIheHKxdHXpci=>	NWHvV\|lkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0NFc3PTNpPkK2OFA4PjV\|PD;hQi=>
H357	NYT1T2tGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:3MlUwOTBizszN	NXfkS4JxPDhiaB?=	NH7sSm5FVVOR	NXfuco5NcW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>?	NIPuV3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwPVg4PCd-Mk[wNFk5PzR:L3G+
TAF	M{Pqe2Z2dmO2aX;uJGF{e2G7	MVGxNOKhyrWP	NUXhOZI6PyCm		MmjGZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN?	NFH4dZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm4O\|EzPyd-MkW5PFcyOjd:L3G+
TAF	NEHBe\|JHfW6ldHnvckBCe3OjeR?=	NFjoVZgyOMLiwsXN	Mni0N\|AuOTJyIH3pci=>		NEXTXmhxd2:{bImgZYZn\WO2czDkRYt1KHCqb4PwbI9zgWyjdHnvckBkd26\|ZYH1[Y51KHSxIFXHSkB{cWewYXzpcoc>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl6N{GyO{c,OjV7OEexNlc9N2F-
TAF	M4i1eGZ2dmO2aX;uJGF{e2G7	MoK4NVDDqML3TR?=	NWfneY1LPDhiaB?=		MVzpcoNz\WG\|ZYOgSWdHWiCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25?	M37mXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUi3NVI4Lz5{NUm4O\|EzPzxxYU6=
PANC-1	NX35R2VXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPkb4IzOC94MD:xNFAh\|ryP	M{fEZ\|I1NzR6L{eyJIg>		NYH2WphocW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NEDEfVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm3N\|A3Oid-MkW5O\|MxPjJ:L3G+
PANC-1	M4XFe2Z2dmO2aX;uJGF{e2G7	M2TnVFIxNzZyL{GwNEDPxE1?	M2q3fFI1KGh?		NFjyOZlifHSnboXheJMh[2WubDDpcpZie2mxbjDhcoQhdWmpcnH0bY9vKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?	M160WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUezNFYzLz5{NUm3N\|A3OjxxYU6=
HeLa	NU\seHFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPvO4ozOMLizszNxsA>	M{XYfVI1yqCq		Mnzx[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25?	MojmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{C0NlMoRjJ3N{ewOFI{RC:jPh?=
SACC-83	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXWZWIzOMLizszNxsA>	MnnUNlTDqGh?		MXflcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd5MESyN{c,OjV5N{C0NlM9N2F-
HeLa	NH3ucGlCeG:ydH;zbZMhSXO\|YYm=	NFW2bZUzOMLizszNxsA>	NGi5c5EzPMLiaB?=		NWHSVnZ2\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>?	M2rZPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{ewOFI{Lz5{NUe3NFQzOzxxYU6=
SACC-83	MmK5RZBweHSxc3nzJGF{e2G7	MnjJNlDDqM7:TdMg	NFzseYgzPMLiaB?=		MXflcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz	MoPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{C0NlMoRjJ3N{ewOFI{RC:jPh?=
HeLa	NH;x[npHfW6ldHnvckBCe3OjeR?=	MmjoNlAwPDBxOECg{txO	MofCNlTDqGh?		Moq1eZBz\We3bHH0d{BRXEWQIIDhdpRq[WyueTDifUBqdmirYnn0bY5oKFOyMTygZY5lKGGldHn2ZZRmeyCSVFXOJIFv\CCrbnHjeIl3[XSnczDBT3Q>	Mo\DQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{C0NlMoRjJ3N{ewOFI{RC:jPh?=
SACC-83	NFPtWGFHfW6ldHnvckBCe3OjeR?=	MmDrNlAwPDBxOECg{txO	MU[yOOKhcA>?		NVfCb2RPfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R?	MlrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{C0NlMoRjJ3N{ewOFI{RC:jPh?=
HLCZ01	MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7VeINPOOLCk{[wxsDDvU1?	NEGxflY1QCCq	MXvEUXNQ	NFLHZpZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M3fsW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K0PFk6Lz5{NUeyOFg6QTxxYU6=
HLCZ01	NWXIV5ljTnWwY4Tpc44hSXO\|YYm=	NVTSb3BqPDEEoN88US=>	MkKxNlQhcA>?	Mke0SG1UVw>?	MVjpcoNz\WG\|ZYOgZYNkfW23bHH0bY9vKG:oIFewM2cyNXCqYYPlJINmdGy\|IHPvcYJqdmWmIIfpeIghUU[QLd8x	NGe1dVQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOFg6QSd-MkW3NlQ5QTl:L3G+
HLCZ01	MUXBdI9xfG:\|aYOgRZN{[Xl?	NVTPOWN2PDEEoN88US=>	NEDsW20zPCCq	M3nOR2ROW09?	NUTqS49H\W6qYX7j[ZMh[XCxcITvd4l{KGOxbXLpcoVlKHerdHigTWZPNc7z	M4DKWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{K0PFk6Lz5{NUeyOFg6QTxxYU6=
HLCZ01	MUHGeY5kfGmxbjDBd5NigQ>?	NYfuXWk3PDEEoN88US=>	M1TuSVI1KGh?	NIfCTo1FVVOR	NX7jcJF4cW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y	NFnKWoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOFg6QSd-MkW3NlQ5QTl:L3G+
MGC803	NX3JfVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPPNE03OCEQvF2=	NF:ydXM4OiCq		MYrJR\|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?=	NF7GTpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUewNVM4QCd-MkW3NFE{Pzh:L3G+
SGC7901	MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTKfpkxNTZyIN88US=>	MWe3NkBp		NULtWYs4UUN3ME20N{42O+LCidMx5qCKPS5zMjFOwG0>	M3;wUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CxN\|c5Lz5{NUewNVM4QDxxYU6=
MGC803	NVLqc2ZCTnWwY4Tpc44hSXO\|YYm=	NWr5ZW5vPDEEoN88US=>	MX:4M\|E3NzJ2IHi=		MX\1dJJm\3WuYYTzJGNjdC2kIHX4dJJme3Orb36=	Mo\3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MEGzO\|goRjJ3N{CxN\|c5RC:jPh?=
SGC7901	NEXVblRHfW6ldHnvckBCe3OjeR?=	Mon0OFDDqM7:TR?=	M1\VSFgwOTZxMkSgbC=>		MkLteZBz\We3bHH0d{BE[mxvYjDlfJBz\XO\|aX;u	NUTqR5ZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NFE{PzhpPkK1O\|AyOzd6PD;hQi=>
MCF-7	Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXixM\|ExKM7:TR?=	MYi3NkBp	NVHRbmRnTE2VTx?=	Mlfm[Y5p[W6lZYOgZ4Ft[2m2cnnvcE1qdmS3Y3XkJINmdGxiZ4Lve5RpKGmwaHnibZRqd25?	NWDEdG45RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2Olc2OTBpPkK1OlY4PTFyPD;hQi=>
MDA-MB-231	NWTCRXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXy3ZpZLOS9zMDFOwG0>	M3vVcVczKGh?	NHGyd\|lFVVOR	MVHlcohidmOnczDjZYxkcXS{aX;sMYlv\HWlZXSgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdg>?	NGHWcVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[2O\|UyOCd-MkW2Olc2OTB:L3G+
MDA-MB-231	MnzpSpVv[3Srb36gRZN{[Xl?	NEnSVlgxNTRyINM1US=>	MUS0MVI1KGh?		Mn34bY5kemWjc3XzJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbjDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M3LZfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUi3N\|I6Lz5{NUW4O\|MzQTxxYU6=
MCF-7	M1ryXmZ2dmO2aX;uJGF{e2G7	MVywMVQxKML3TR?=	MVe0MVI1KGh?		MVrlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW\|c3nvcuKh	NHTqcXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW4O\|MzQSd-MkW1PFc{Ojl:L3G+
MCF7-MX	MVjGeY5kfGmxbjDBd5NigQ>?	MmG3NE01OCEEtV2=	MWm0MVI1KGh?		NULQd2w5\W6qYX7j[ZMhfGinIHXm[oVkfHNib3[gWHBCKG:wIFHCR2czKGW6cILld5Nqd28EoB?=	M4fOUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUi3N\|I6Lz5{NUW4O\|MzQTxxYU6=
MDA-MB-231	MorxSpVv[3Srb36gRZN{[Xl?	MmnTNE01OCEEtV2=	M2TwdFQuOjRiaB?=		MWPzeIlufWyjdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGFDS0d{IIXwJJRwKDRwMkegeIlu\XNidH:gZ49vfHKxbDDs[ZZmdCCkeTCxNkBpyqB?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV6N{OyPUc,OjV3OEezNlk9N2F-
A2780	Mn\sSpVv[3Srb36gRZN{[Xl?	Moq0OU8yOC9zNTFOwG0>	MV[0PEBp		MYDk[YNz\WG\|ZYOgR495NTJiZYjwdoV{e2mxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NGnsWo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOFg6QCd-MkW0NlQ5QTh:L3G+
SKOV3	MUDGeY5kfGmxbjDBd5NigQ>?	NITZSYk2NzFyL{G1JO69VQ>?	MV:0PEBp		MnL5[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NUHjeW9IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlQ5QThpPkK1OFI1QDl6PD;hQi=>
A2780	NWe5NYJDTnWwY4Tpc44hSXO\|YYm=	NFizTJA2NzFyL{G1JO69VQ>?	NFfNd2s1QCCq		Mlzy[YxmfmG2ZYOgeIhmKGW6cILld5Nqd25ib3[gSU1k[WSqZYLpckBidmRia3XyZZRqdg>?	MnK3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MkS4PVgoRjJ3NEK0PFk5RC:jPh?=
SKOV3	NV\ZWZE{TnWwY4Tpc44hSXO\|YYm=	M4Wwd\|UwOTBxMUWg{txO	Mm\tOFghcA>?		NH;FWldmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR{NEi5PEc,OjV2MkS4PVg9N2F-
A2780	Mn\FSpVv[3Srb36gRZN{[Xl?	M4nwfFUwOTBxMUWg{txO	MXe0PEBp		M3TSV4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?=	Mkf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MkS4PVgoRjJ3NEK0PFk5RC:jPh?=
SKOV3	NF3xTWtHfW6ldHnvckBCe3OjeR?=	MWi1M\|ExNzF3IN88US=>	NGLjUno1QCCq		M2nDTIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBPNWOjZHjldolvKGGwZDDWbY1mdnSrbh?=	NUDySFdkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlQ5QThpPkK1OFI1QDl6PD;hQi=>
A2780	M2XnW2Z2dmO2aX;uJGF{e2G7	MVy1M\|ExNzF3IN88US=>	M4[3e\|EhcA>?		NHrpV5JqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NXPFUotMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlQ5QThpPkK1OFI1QDl6PD;hQi=>
SKOV3	NX;oe5lNTnWwY4Tpc44hSXO\|YYm=	M2GzVlUwOTBxMUWg{txO	MX2xJIg>		MU\pcoNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NF3MSJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOFg6QCd-MkW0NlQ5QTh:L3G+
HCT-15	MWTGeY5kfGmxbjDBd5NigQ>?	NVHOT3ZGOTBvNUCg{txO	M2XJO\|YuOzZiaB?=		NGrxdJRqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	NWjJZpo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVgxOjhpPkK1NlE5ODJ6PD;hQi=>
HT-29	NYX5c45wTnWwY4Tpc44hSXO\|YYm=	MYKxNE02OCEQvF2=	MY[2MVM3KGh?		MkjhbY5lfWOnczD0bIUh\XiycnXzd4lwdiCxZjDDU3guOiCrbjDic5RpKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70JI1idm6nch?=	NGPrNVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKxPFAzQCd-MkWyNVgxOjh:L3G+
HSC3	Ml:5R4VtdCCYaXHibYxqfHliQYPzZZk>	M3rVT\|DjiJN2MDFOwG0>	Mlm4OFghcA>?		NH7zOYhKSzVyPUK1MlXDuTFwN{iwJO69VQ>?	M4r0fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUm4O\|g6Lz5{NUG5PFc5QTxxYU6=
HSC3	NU\uUJhuSXCxcITvd4l{KEG\|c3H5	M2nwfFI2KM7:TR?=	NEjRbJM1QCCq		MnHMbY5lfWOnczDhdI9xfG:\|aYO=	NEfP[oQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG5PFc5QSd-MkWxPVg4QDl:L3G+
HSC3	Ml\TSpVv[3Srb36gRZN{[Xl?	NVjiUGNvOjVizszN	MkfVOFghcA>?		MWLlfIhq[mm2czDzbYdvcW[rY3HueIx6KHKnZIXj[YQhdWmpcnH0bY9vKGOxbXLpcoVlKHerdHigR2VV	M4mweVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUm4O\|g6Lz5{NUG5PFc5QTxxYU6=
HSC3	NFnoUGRHfW6ldHnvckBCe3OjeR?=	MXyyOUDPxE1?	MV:0PEBp		NWXJbVFMcW6qaXLpeJMhUFOFMzDj[YxtKGmwdnHzbY9vKGOxbXLpcoVlKHerdHigR2VV	NH7kN5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG5PFc5QSd-MkWxPVg4QDl:L3G+
HSC3	NYjTVGZyTnWwY4Tpc44hSXO\|YYm=	Ml\xNlUh\|ryP	MnS2O\|IhcA>?		NEn0SHNl\WO{ZXHz[ZMhVU2SLUKgZY5lKE2PUD25JJBzd3SnaX7zxsA>	NESwUpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG5PFc5QSd-MkWxPVg4QDl:L3G+
201T	NEHoc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEP2cVU4OiCq	MlXSSG1UVw>?	M3HaSmlEPTB;NEiuOkDDvU1?	NVXJOlhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVc6PDFpPkK1NFU4QTRzPD;hQi=>
273T	NGiyZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFf1N4Y4OiCq	NIPQe\|BFVVOR	NIDOU3hKSzVyPUiwMlUhyrWP	MnywQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUe5OFEoRjJ3MEW3PVQyRC:jPh?=
Hep-2	M3zoVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvBUGNTOzBxNUCvNVAxKM7:TR?=	NEjrSHIyOi9{ND:zOk81QCCq	MmnnSG1UVw>?	MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MnvqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUi1OlQoRjJ2OUm4OVY1RC:jPh?=
Hep-2	NHvxOHdCeG:ydH;zbZMhSXO\|YYm=	MVe1NEDPxE1?	M{C3XVAuPDhiaB?=	NYHi[YQ2TE2VTx?=	M1TkNolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MoGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUi1OlQoRjJ2OUm4OVY1RC:jPh?=
Hep-2	MoTTSpVv[3Srb36gRZN{[Xl?	NIPGZVg2OCEQvF2=	Mmq0NE01QCCq	M4H1ZWROW09?	MXzy[YR2[2W\|IITo[UB1\WyxbXXyZZNmKGGldHn2bZR6KGe{YXT1ZYxtgQ>?	M37VeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm4OVY1Lz5{NEm5PFU3PDxxYU6=
Hep-2	M4XJdmZ2dmO2aX;uJGF{e2G7	MYi1NEDPxE1?	MXmwMVQ5KGh?	M2j1dWROW09?	NGG0cVVl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>?	NVLabFlFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVg2PjRpPkK0PVk5PTZ2PD;hQi=>
SGC-7901	NEe1blZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXjNVAwPTBxMUCwJO69VQ>?	NVX5cWNqOjRxNEivO\|IhcA>?	MnzCSG1UVw>?	NV\ZNG9mcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NFWxRYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5Nlk2QCd-MkS5PVI6PTh:L3G+
MKN-45	NGiwcGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjt[WcyOC93MD:xNFAh\|ryP	NWTNN\|BJOjRxNEivO\|IhcA>?	MX7EUXNQ	MV\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	M{D1N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUmyPVU5Lz5{NEm5Nlk2QDxxYU6=
SGC-7901	NY\PSXBsTnWwY4Tpc44hSXO\|YYm=	MX:xNE82OC9zMECg{txO	MVK0PEBp	NF2xSJhFVVOR	MkDp[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NF7mfpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5Nlk2QCd-MkS5PVI6PTh:L3G+
MKN-45	MnuwSpVv[3Srb36gRZN{[Xl?	MVWxNE82OC9zMECg{txO	NGfZcZo1QCCq	M2LpV2ROW09?	Ml64[I94dnKnZ4XsZZRmeyC2aHWgcXJPSSCneIDy[ZN{cW:wIHzleoVteyCxZjDDU3guOiCjbnSgVGNPSSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MnrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUK5OVgoRjJ2OUmyPVU5RC:jPh?=
C666-1	MlThR5l1d3SxeHnjbZR6KEG\|c3H5	M2XnU\|IxNThyIN88US=>	NVOw[plYOjRiaB?=		NGXHOZFl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh	M1;IR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW0PFM5Lz5{NEi1OFg{QDxxYU6=
CNE-1	NGnhdIFEgXSxdH;4bYNqfHliQYPzZZk>	NIHNZpMzOC16MDFOwG0>	MnO0NlQhcA>?		M2DJfIRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>	MojaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUS4N\|goRjJ2OEW0PFM5RC:jPh?=
CNE-2	NYnCSXdoS3m2b4TvfIlkcXS7IFHzd4F6	Mo\PNlAuQDBizszN	M{LpTlI1KGh?		MWjk[YNz\WG\|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg	Mn[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUS4N\|goRjJ2OEW0PFM5RC:jPh?=
C666-1	M17jdGN6fG:2b4jpZ4l1gSCDc4PhfS=>	NHP2PVg3OCEQvF2=	M13B[Fch\A>?		NV7Le5N7\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI>	MorUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUS4N\|goRjJ2OEW0PFM5RC:jPh?=
CNE-1	NVXVWHBqS3m2b4TvfIlkcXS7IFHzd4F6	NWXYb4dpPjBizszN	NHPXe\|E4KGR?		NETLVYlmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=>	MlfwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUS4N\|goRjJ2OEW0PFM5RC:jPh?=
SNU-1041	NHvBVJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfHSFNJOC12MDFOwG0>	M{HVT\|Q5KGh?		NUG3WJVvcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NWjmPGlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PVI4ODNpPkK0OlkzPzB\|PD;hQi=>
SNU-1041	MoS1SpVv[3Srb36gRZN{[Xl?	MX:yNE8{OCEQvF2=	MXm0JIg>		NUDGZZhEcW6mdXPld{BmgHC{ZYPzbY9vKG:owrDDTG9RNCCJUmC3POKh[W6mwrDYRnAyyqCjdDD0bIUhWk6DIHzleoVtyqB?	NVXNNpc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PVI4ODNpPkK0OlkzPzB\|PD;hQi=>
SNU-1041	NHnV[JJHfW6ldHnvckBCe3OjeR?=	NE\1U\|UxNTRyIN88US=>	MUe0JIg>		Mn;XeZAuemWpdXzheIV{KEOKT2FCpIFnfGW{IITy[YF1dWWwdDD3bZRpKGirZ3igZ49v[2WwdILheIlwdnN?	NUjoeW92RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PVI4ODNpPkK0OlkzPzB\|PD;hQi=>
SGC-7901	NXT6SIdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H4bVUxNTF{NTFOwG0>	NYLEUmhuOjRxNEivO\|IhcA>?		M2W0OYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NW\TdnVkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|Y{QTRpPkK0Olc3Ozl2PD;hQi=>
SGC-7901	MYfBdI9xfG:\|aYOgRZN{[Xl?	M1\JPVExOCEQvF2=	MVu3NkBp		NWXNPGhZcW6mdXPld{BieG:ydH;zbZM>	M{iydFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nke2N\|k1Lz5{NE[3OlM6PDxxYU6=
SGC-7901	MVPGeY5kfGmxbjDBd5NigQ>?	MmD1O\|UwOTByL{GyOUDPxE1?	MnvDNlQwPDhxN{KgbC=>		NX73R3B5cW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO\|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI>	M1PnWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Nke2N\|k1Lz5{NE[3OlM6PDxxYU6=
LMeC	NXOxT4J[TnWwY4Tpc44hSXO\|YYm=	Mn3UNlAwPTBizszN	MYC0PEBp		NFu1dVhl\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhS0:[LUKgdJJwfGWrbh?=	M{T6blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW2O\|Q3Lz5{NE[1Olc1PjxxYU6=
CMeC-1	NH\4doRE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MkfvNlAwPTBizszN	MXW0PEBp		NUfsUJRUcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3Nke0Okc,OjR4NU[3OFY9N2F-
LMeC	MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NV;v[YVSOjBxNUCg{txO	M2fFWFQ5KGh?		MX\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3Nke0Okc,OjR4NU[3OFY9N2F-
CMeC-1	M2W3[mZ2dmO2aX;uJGF{e2G7	M{PGWlIxNzVyIN88US=>	NGTzNmg1QCCq		M3fJSolv\HWlZYOgS\|EuWyCjcoLld5Q>	NGXDdVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1Olc1Pid-MkS2OVY4PDZ:L3G+
LMeC	M3;WXGZ2dmO2aX;uJGF{e2G7	NWjZdVdROjBxNUCg{txO	Mkn3OFghcA>?		NHfPNmxqdmS3Y3XzJGcyNVNiYYLy[ZN1	M3:xXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW2O\|Q3Lz5{NE[1Olc1PjxxYU6=
CMeC-1	NWnGVZhQTnWwY4Tpc44hSXO\|YYm=	NWnnNYRsOjBxNUCg{txO	NEDMN2w1QCCq		M1zlPYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M2rqZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW2O\|Q3Lz5{NE[1Olc1PjxxYU6=
LMeC	NEjsNWxHfW6ldHnvckBCe3OjeR?=	NGS3UGkzOC93MDFOwG0>	NIHpTm41QCCq		NWm3NGE4\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MlfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NU[3OFYoRjJ2NkW2O\|Q3RC:jPh?=
CMeC-1	M4nWd2Z2dmO2aX;uJGF{e2G7	M4rkZVIxNzVyIN88US=>	MUK0PEBp		MYfpcoR2[2W\|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3Nke0Okc,OjR4NU[3OFY9N2F-
LMeC	NWni[2NSTnWwY4Tpc44hSXO\|YYm=	M17VbFIxNzVyIN88US=>	NEPpeYE1QCCq		NEjRPFBqdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3Nke0Okc,OjR4NU[3OFY9N2F-
OVCAR-3	MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M2n2e\|ExKML3TR?=	MoTENUBp		MoTI[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=>	NIf4XY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyNFIzPyd-MkS1NlAzOjd:L3G+
OVCAR-3	M{XRT2Fxd3C2b4Ppd{BCe3OjeR?=	NVTQSmF5OTBiwsXN	NEXiU4UyKGh?		NV7kNW5ReHKxbX;0[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGGyb4D0c5Nqe8Li	NUmwTG1lRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NlAzOjdpPkK0OVIxOjJ5PD;hQi=>
OVCAR-3	MnjWSpVv[3Srb36gRZN{[Xl?	NE\BSm0yOCEEtV2=	NUD0OXh2OSCq		MVPlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmNToEoB?=	M2LVO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUKwNlI4Lz5{NEWyNFIzPzxxYU6=
OVCAR-3	MWTGeY5kfGmxbjDBd5NigQ>?	MWSxNEDDvU1?	NVrJcIFIOSCq		MVTkc5dvNXKnZ4XsZZRmeyCQRj5OvmIh[WO2aY\heIlwdiCrbnT1Z4VlKGK7IIDhZ4xqfGG6ZXy=	NVizdGV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NlAzOjdpPkK0OVIxOjJ5PD;hQi=>
OVCAR-3	Mor6SpVv[3Srb36gRZN{[Xl?	MVqxNEDDvU1?	M{fPUlEhcA>?		NWmyPFFNcW6qaXLpeJMheGGlbHn0ZZhmdC2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25?	NWPoPWVWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NlAzOjdpPkK0OVIxOjJ5PD;hQi=>
CF33	NHvwZpJHfW6ldHnvckBCe3OjeR?=	MXOxNFAh\|ryP	M2nmR\|I1KGh?		NUTZSZI1cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36=	NWX4bXU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFM4QDJpPkK0OVA{Pzh{PD;hQi=>
CF33	M1jCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYexNE0yODBizszN	MmTZNE01KGR?		NGn1fIRqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NHfSNGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWwN\|c5Oid-MkS1NFM4QDJ:L3G+
CF33	NXnCeJZ6TnWwY4Tpc44hSXO\|YYm=	MXmxNE0yODBizszN	Mm\NOE0zPCCq		MWjk[YNz\WG\|ZYOgZ4VtdHNiaX6geIhmKFNicHjhd4Uh[W6mIHnuZ5Jm[XOnczDj[YxteyCrbjDHNE9IOSCjcoLld5Q>	MkDOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEO3PFIoRjJ2NUCzO\|gzRC:jPh?=
LNCaP	MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXaVlBlOi93L{GwJO69VQ>?	MlnuPVYhcA>?		MonjbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?=	NW[zfIsyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVY6PzhpPkK0Nlk3QTd6PD;hQi=>
LNCaP	MlrGRZBweHSxc3nzJGF{e2G7	NFvnVIIzNzVxMUCg{txO	Ml3FPVYhcA>?		NHjvbXpqdmS3Y3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIHH0c5J3[XO2YYTpci=>	NGHW[ng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5Olk4QCd-MkSyPVY6Pzh:L3G+
PC-3	MmntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGi3fXAxNTVyIN88US=>	NILTZWw1QOLCiXi=		MoTzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NVGxe2s2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlc5QDJpPkK0NVI4QDh{PD;hQi=>
PC-3	MnrrR4VtdCCYaXHibYxqfHliQYPzZZk>	MlO5NE0yODBizszN	MYm3NkBp		NHjNbJNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M3HDRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUK3PFgzLz5{NEGyO\|g5OjxxYU6=
HCA-7	NYXG[HdKTnWwY4Tpc44h[XO\|YYm=		NEnBV4Y4OiCqcoO=		M4PYXmlvcGmkaYTpc44hd2ZiSVytNYJmfGFvaX7keYNm\CCSR1WyJJBzd2S3Y4Tpc44hcW5iaIXtZY4hUEODLUegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEWLQTygSWM2OCB;IECuNFAyOTVizszNMi=>	NH7WdFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWxOlI5Oid-MkK1NVYzQDJ:L3G+
CHO	NGrWe29HfW6ldHnvckBie3OjeR?=				MYLJckB3cXS{bzDpcohq[mm2b4L5JJBwfGWwY4mgZYdicW6\|dDDoeY1idiCFT2itNkBqdiC\|dHHicJkhfHKjboPm[YN1\WRiY3jpcoV{\SCqYX3zeIVzKG:4YYL5JEhEUE9rIHPlcIx{NCCLQ{WwJF0hOC5yMEKg{txONg>?	Mmi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB3N{[2PFQoRjFyNUe2Olg1RC:jPh?=
CHO	MYHGeY5kfGmxbjDhd5NigQ>?				NVW4SZE1UW6qaXLpeIlwdiCxZjDQS2UuOiCycn;keYN1cW:wIHnuJGNJVyClZXzsd{BmgHC{ZYPzbY5oKGi3bXHuJGNQYC1{LDDJR\|UxKD1iMD6wNFIh\|ryPLh?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODV5Nk[4OUc,OTB3N{[2PFU9N2F-
CHO	Ml\ZSpVv[3Srb36gZZN{[Xl?				M1rJT2lvKH[rdILvJJBwfGWwY4mgZYdicW6\|dDDoeY1idiCScn;zeIFodGGwZHnuJGcwUCC\|eX70bIF{\SB{IHnuJJRz[W6\|ZnXjeIVlKEOKTzDj[YxteyxiSVO1NEA:KDBwMECyJO69VS5?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODF7N{m3NEc,OTBzOUe5O\|A9N2F-
CHO	NXrBR\|hWTnWwY4Tpc44h[XO\|YYm=				M4O5Z2lvcGmkaYTvdpkhd2ZiaIXtZY4hWHKxc4Th[4xidmSrbjDHM2ghe3mwdHjhd4UhOiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzMEBKSzVyIE2gNE4xODJizszNMi=>	M{T5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkSzPVQzLz5zMk[0N\|k1OjxxYU6=
synovial cells	NV7uVGJnTnWwY4Tpc44h[XO\|YYm=				NYixTpBtUW6qaXLpeI9zgSCnZn\lZ5Qhd25icILv[JVkfGmxbjDv[kBkgWOub3;4fYdmdmG\|ZT2yJEhEV1hvMjmgdJJwe3SjZ3zhcoRqdiCHMjCoVGdGOiliaX6gbJVu[W5iSVyxMYJmfGFic4TpcZVt[XSnZDDzfY5wfmmjbDDj[YxteyxiSVO1NEA:KDBwMEC3PUDPxE1w	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODh{MUexOkc,OTB6MkG3NVY9N2F-
RAW264.7	NVzscGwzTnWwY4Tpc44h[XO\|YYm=				MlPZTY5pcWKrdHnvckBw\iCFT2itNkBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCOUGOtbY5lfWOnZDDQS2UzKHC{b3T1Z5Rqd25idILlZZRm\CCycnnvdkB1dyCOUGOgZ4hidGynbnflJIJ6KGWweont[UBqdW23bn;hd5NigSxiSVO1NEA:KDBwMEC4O{DPxE1w	MlrhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NU[2OlIoRjJ2NkW2OlYzRC:jPh?=
HEK293	MXzGeY5kfGmxbjDhd5NigQ>?				M3vwVWlvcGmkaYTpc44hd2ZiY3zvcoVlKFO2eXzvdIhwemFicHnzeIltdGG2YTDhcJBp[S2FQTDlfJBz\XO\|ZXSgbY4hcHWvYX6gTGVMOjl\|IHPlcIx{KGK7IIP0c5Bx\WRvZnzve{BEVzJiYYPzZZktKEurIE2gNE4xOzR{IN88UU4>	MnTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3MkC1O\|coRjF7NUKwOVc4RC:jPh?=
SF9	NYPqOplnTnWwY4Tpc44h[XO\|YYm=				NX73U2I2UW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHBzd3O2YXfsZY5lcW5iRz;IJJN6dnSqYYPlJFIh\XiycnXzd4VlKGmwIIPmMVkh[2WubIOgbY5n\WO2ZXSge4l1cCCkYXP1cI93cXK3czygTWM2OCB;IECuNFM3KM7:TT6=	M4TwWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2Nkm4NVkxLz5zNE[5PFE6ODxxYU6=
SF9	Mlu2SpVv[3Srb36gZZN{[Xl?				M2nYZWlvKH[rdILvJIlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDy[YNwdWKrbnHueEBxem:\|dHHncIFv\GmwIFevTEB{gW62aHHz[UAzKGW6cILld5Nm\CCrbjDz[k06KGOnbHzzJIlv\mWldHXkJJdqfGhiYnHjeYxwfmm{dYOsJGlEPTBiPTCwMlA{PiEQvF2u	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTB{NkC1NEc,OTVyMk[wOVA9N2F-
CHO	MWHGeY5kfGmxbjDhd5NigQ>?				MknMTY5pcWKrdHnvckBw\iCFT2iyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjcnHjbIlld26rYzDhZ4llNXO2aX31cIF1\WRiUFfFNkBxem:mdXP0bY9vKGK7IHXufplu\SCrbX31co9ie3OjeTygTWM2OCB;IECuNFM3KM7:TT6=	MnzQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV3Nk[yPVAoRjF3NU[2NlkxRC:jPh?=
insect cells	NYO2T3h1TnWwY4Tpc44h[XO\|YYm=		MYSxJI1qdg>?		NFH6SFJKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFPPXFIh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{B2e2mwZzDhdoFkcGmmb37pZ{Bi[2mmIHHzJJN2[nO2cnH0[UBqdmO3YnH0[YQh\m:{IEGgcYlvKHC{aX;yJJRwKHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCob4KgNlUhe2WlczDifUBVVVCGLXLhd4VlKGOqcn;tc4dmdmmlIHHzd4F6NCCLQ{WwJF0hOC5yNEKg{txONg>?	M4nQSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGwNlcxLz5{M{CxNFI4ODxxYU6=
HNSCC 1483	M33XN2Z2dmO2aX;uJIF{e2G7		MnnlN\|AhdWmwcx?=		NWPDVGtqUW6qaXLpeIlwdiCxZjDDU3guOiCrbjDoeY1idiCKTmPDR{AyPDh\|IHPlcIx{KHW\|aX7nJHsyPEOfIHHyZYNpcWSxbnnjJIFkcWRiYYOgd5Vje3S{YYTlJJBz\WmwY4XiZZRm\CCob4KgN\|AhdWmwczDi[YZwemVic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDNyIH3pcpMtKEmFNUCgQUAxNjB3NDFOwG0v	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4M{i5OEc,OjJ{NkO4PVQ9N2F-
J774	NYPUXpJ2TnWwY4Tpc44h[XO\|YYm=				MUHJcohq[mm2aX;uJI9nKEORWEKgbY4hVFCVLYP0bY12dGG2ZXSgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHBITTJibHX2[Yx{KGK7IILh[IlwcW2vdX7vZZN{[XluIFnDOVAhRSByLkC2JO69VS5?	NGrIV5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{mxOVg2PCd-MUe5NVU5PTR:L3G+
J774	MVPGeY5kfGmxbjDhd5NigQ>?		NXjwe5JjOTVibXnudy=>		NHLWRnpKdmirYnn0bY9vKG:oIFPPXFIhcW5iTGDTMZN1cW23bHH0[YQhdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHBITTJicILv[JVkfGmxbjDh[pRmeiBzNTDtbY5{KGK7IILh[IlwcW2vdX7vZZN{[XluIFnDOVAhRSByLkC2JO69VS5?	NG\6PY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1Nlk2Pyd-MUi3OVI6PTd:L3G+
J774	NIP5XGhHfW6ldHnvckBie3OjeR?=		NGHWfWIzPCCqcoO=		M1vqUWlvcGmkaYTpc44hd2ZiQ1;YMVIudWWmaXH0[YQhWEeHMjDwdo9lfWO2aX;uJIlvKEySUz3zeIlufWyjdHXkJI1wfXOnIFq3O\|Qh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IILh[IlwcW2vdX7vZZN{[XluIFnDOVAhRSByLkC2NUDPxE1w	NXS0UlNZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5PVIyPzZpPkKxPVkzOTd4PD;hQi=>
J774	NEPVT2ZHfW6ldHnvckBie3OjeR?=				MXjJcohq[mm2aX;uJI9nKEORWEKgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKFCJRUKgdJJw\HWldHnvckBjgSC{YXTpc4ludXWwb3Hzd4F6NCCLQ{WwJF0hOC5yNkGg{txONg>?	Mn7QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEC0OFQoRjJ\|NkiwOFQ1RC:jPh?=
SF9	M33oOWZ2dmO2aX;uJIF{e2G7				M3XMdmlvcGmkaYTpc44hd2ZiaIXtZY4hS0:[MjDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNvaX7m[YN1\WRiU1[5JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYYLhZ4hq\G:waXOgZYNq\C2\|dHnteYxifGWmIGDHSVIheHKxZIXjeIlwdiC2cnXheIVlKDFiaIKgZoVnd3KnIHHyZYNpcWSxbnnjJIFkcWRiY3jhcIxmdmenIHL5JIVvgnmvZTDpcY12dm:jc4PhfUwhUUN3MDC9JFAvODZ\|IN88UU4>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV{MEW3N{c,OTl3MkC1O\|M9N2F-
COS	MX\GeY5kfGmxbjDhd5NigQ>?				MVvJcohq[mm2aX;uJI9nKGi3bXHuJIN6[2yxb4j5[4Vv[XOnLUKg[ZhxemW\|c3XkJIlvKEORUzDj[YxteyxiSVO1NEA:KDBwME[4JO69VS5?	NEXEb\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUS1OFI1Oid-MUW0OVQzPDJ:L3G+
COS	Ml\lSpVv[3Srb36gZZN{[Xl?				M1zYdWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:[MjDlfJBz\XO\|ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliQ1;TJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYYLhZ4hq\G:waXOgZYNq\C2\|dHnteYxifGWmIGDHSVIheHKxZIXjeIlwdiC2cnXheIVlKDFiaIKgZoVnd3KnIHHyZYNpcWSxbnnjJIFkcWRiY3jhcIxmdmenIHL5JIVvgnmvZTDpcY12dm:jc4PhfUwhUUN3MDC9JFAvODZ6IN88UU4>	Ml;qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3MkC1O\|MoRjF7NUKwOVc{RC:jPh?=
143982	MkXRSpVv[3Srb36gZZN{[Xl?				MY\JckB3cXS{bzDpcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUILvd5Ri\2yjbnTpckBIN0hic4nueIhie2ViMjCoR29ZNTJrIHnuJFE1Ozl6MjDj[YxteyxiSVO1NEA:KDBwMEe5JO69VS5?	NX\kVY1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK4O\|c2QDRpPkGyPFc4PTh2PD;hQi=>
J774	MWnGeY5kfGmxbjDhd5NigQ>?				MljQTY4hfmm2cn:gbY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JHBzd3O2YXfsZY5lcW5iRz;IJJN6dnSqYYPlJFIhcW5ibYXybY5mKEp5N{SgZ4VtdHNuIFnDOVAhRSByLkC3PUDPxE1w	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh3N{G0PUc,OTV6NUexOFk9N2F-
J774	NEO4XZBHfW6ldHnvckBie3OjeR?=				M{\KNWlvcGmkaYTpc44hd2ZiQ1;YNk1l\XCnbnTlcpQhWEeHMjDwdo9lfWO2aX;uJIlvKEySUz3zeIlufWyjdHXkJI1wfXOnIFq3O\|Qh[2WubIOgZpkhWkmDLDDJR\|UxKD1iMD6wO\|kh\|ryPLh?=	M3rFUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUW3PVMyLz5zOUm1O\|k{OTxxYU6=
osteosarcoma cells	MlLYSpVv[3Srb36gZZN{[Xl?				M{XzcmlvcGmkaYTpc44hd2ZiUILvd5Ri\2yjbnTpckBIN0hic4nueIhie2ViMjDpckAyPDNwOUiuNkBnem:vIHj1cYFvKG:\|dHXvd4Fz[2:vYTDj[YxteyxiSVO1NEA:KDBwMEig{txONg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTR4Mkm3Okc,OTF2NkK5O\|Y9N2F-
SF9	MY\GeY5kfGmxbjDhd5NigQ>?				MnjvTY5pcWKrdHnvckBw\iCqdX3hckBEV1h{IHX4dJJme3OnZDDpckB{\jliY3XscJMtKEmFNUCgQUAxNjB6IN88UU4>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjJ3MkmxO{c,OTZ{NUK5NVc9N2F-
RAW264.7	MV7BcpRqcW6obHHtcYF1d3K7IHHzd4F6				NULxO2J[SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJHBITTJicILv[JVkfGmxbjygTWM2OCB;IECuNUDPxE1w	NXqzN2w6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNFA6PDhpPkKyNFAxQTR6PD;hQi=>
RAW264.7	NIjrb3hHfW6ldHnvckBie3OjeR?=				NHTkeoFKdmirYnn0bY9vKG:oIFPPXE0zKGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFzQV{1qdmS3Y3XkJHBITTJicILv[JVkfGmxbjygTWM2OCB;IECuNVIh\|ryPLh?=	M3LWXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{WzO\|QyLz5{M{O1N\|c1OTxxYU6=
Sf21	MWHGeY5kfGmxbjDhd5NigQ>?				M13LVmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iTj30[ZJucW6jbDDIbZMufGGpZ3XkJGNQYDJiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoMkGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKHC{b4P0ZYdt[W6maX6gdJJw\HWldHnvckBjgSCnbor5cYUhcW2vdX7vZZN{[XluIFnDOVAhRSByLkG1JO69VS5?	NY\STIE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmzO\|MzPzFpPkK5N\|c{OjdzPD;hQi=>
Sf21	M{TZeWZ2dmO2aX;uJIF{e2G7		MV61JI1qdnN?		NITT[GhKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JG4ufGW{bXnuZYwhUGm\|Nj30ZYdo\WRiaIXtZY4hS0:[LUKg[ZhxemW\|c3XkJIlvKEKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmNlEh[2WubIOgeZNqdmdiYYLhZ4hq\G:waXOgZYNq\CCjczDzeYJ{fHKjdHWgdJJmcW6ldXLheIVlKG[xcjC1JI1qdnNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IEGgbJItKEmFNUCgQUAxNjJ4IN88UU4>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ7M{e5OUc,OzB{OUO3PVU9N2F-
MC9	NWLBVopZTnWwY4Tpc44h[XO\|YYm=				M2\qRmlvcGmkaYTpc44hd2ZiUFfGNoFxcGFicILv[JVkfGmxbjDpckBiemGlaHnkc45q[yCjY3nkMZN1cW23bHH0[YQhdW:3c3WgUWM6KGOnbHzzMEBKSzVyIE2gNE4{KM7:TT6=	NYf3UVRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0PVgyPTBpPkG4OFk5OTVyPD;hQi=>
MC9	NF;VXIRHfW6ldHnvckBie3OjeR?=				M{fL[mlvcGmkaYTpc44hd2ZiUFfGNoFteGijIIDyc4R2[3Srb36gbY4hdW:3c3WgUWM6KGOnbHzzMEBKSzVyIE2gNE41KM7:TT6=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR7OEG1NEc,OTh2OUixOVA9N2F-
293E	NXTsOpRvTnWwY4Tpc44h[XO\|YYm=				M4nyTWlvcGmkaYTpc44hd2ZiaIXtZY4hdWmlcn;zc41idCCSR1XTNUBmgHC{ZYPz[YQhcW5iMkmzSUBk\WyuczDifUBNSy:PUz;NV{BidmGueYPpd{whUUN3MDC9JFAvPDJ3IN88UU4>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3M{G4NEc,OjZ4NUOxPFA9N2F-
SF9	MoLsSpVv[3Srb36gZZN{[Xl?		MlL5NVUhdWmwcx?=		Ml7RTY5pcWKrdHnvckBw\iCodXzsJIxmdme2aDDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGdUXC22YXfn[YQhUESDQ{[g[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIIPmPUBk\WyuczD1d4lv\yCEb3OtUJl{NSiDYzmtRW1EKGG\|IIP1ZpN1emG2ZTDwdoVqdmO3YnH0[YQh\m:{IEG1JI1qdnNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IE[wJI1qdnNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE43PDNizszNMi=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVyMEGzNEc,Ojl3MECxN\|A9N2F-
HT-29	MkH6R5l1d3SxeHnjbZR6KGG\|c3H5		NX;lNXZCPDhiaILz		M1z5e2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEORWD2yJJBwe2m2aY\lJIh2dWGwIFjUMVI6KGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigR2Q1PHZ4c3jSUmEh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwNzFOwG0v	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
SF9	M3XTRWZ2dmO2aX;uJIF{e2G7		NG\wSG0yPSCvaX7z		NID0ZVlKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGxmcXOqbXHubYEh\G:wb4\hcokh[2ijZ3HzbUBj\XSjLXPhdoJwdmmlIHHubJllemG\|ZTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiaX7z[YN1KFOoOTDj[YxteyCrbnP1ZoF1\WRiZn;yJFE2KG2rboOgdJJqd3JidH:geIV{fGmwZzDifUB{fG:ycHXkJIZtd3diQ1:yJIh6\HKjc3WgZZN{[XluIFvpJF0hOC55MEWg{txONg>?	NXq0blFrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5O\|c6PjBpPkKzPVc4QTZyPD;hQi=>
HCA-7	NX7WUppxS3m2b4TvfIlkcXS7IHHzd4F6		MWO0PEBpenN?		M3Xy[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KEORWD2yJJBwe2m2aY\lJIh2dWGwIFjDRU04KGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigR2Q1PHZ4c3jSUmEh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwN{Wg{txONg>?	Mk\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUW3PFcoRjJ2Mkm1O\|g4RC:jPh?=
HepG2	NUnQO2t5SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MorHOFghcHK\|		MoTpRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLke2JO69VS5?	NFXCN5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0OlM3Pyd-Mk[zOFY{Pjd:L3G+
SF9	M1XZ[mZ2dmO2aX;uJIF{e2G7		NGjtRVYyPSCvaX7z		NGPPVmRKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJJJm[2:vYnnuZY51KGi3bXHuJGMufGW{bXnuZYwhTkyDRz;IbZMufGGpZ3XkJGhFSUNzIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkmgZ4VtdHNidYPpcochSm:lLVz5d{0pSWNrLVHNR{BieyC\|dXLzeJJifGVicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB4MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3NuIFnDOVAhRSBzLkG4OUDPxE1w	NWLMWW5ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NFAyOzBpPkK5OVAxOTNyPD;hQi=>
RAW264.7	MlnvRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?		Mk\3NVghcHK\|		MWrBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW\|I3PC55IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRiVF7GMYFteGijIIPlZ5JmfGmxbjDh[pRmeiBzODDodpMh[nlic3Hu[Jdq[2hiRVzJV2EtKEmFNUCgQUAyNjJ6IN88UU4>	MlHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{m0OFEoRjJ2Nke5OFQyRC:jPh?=
APC10.1	MlnyR5l1d3SxeHnjbZR6KGG\|c3H5		NFOwXHg1QCCqcoO=		MX;DfZRwfG:6aXPpeJkh[WejaX7zeEBEV1hvMjDwc5NqfGm4ZTDtc5V{\SCDUFOxNE4yKGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigR2Q1PHZ4c3jSUmEhd3[ncnX4dJJme3OrbnegTGFUNTJiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGuN{DPxE1w	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
RAW264.7	MmLPRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?		MWCzNEBucW6\|		NXXRT4FLSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJI5qfHKrYzDvfIll\SCycn;keYN1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiM{CgcYlveyCob3zsc5dm\CCkeTDMVHMhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KEe{aXXzd{Bie3OjeTygTWM2OCB;IEGuOkDPxE1w	NXPJOlM3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OFQxQThpPkK2OFQ1ODl6PD;hQi=>
COS	MYXGeY5kfGmxbjDhd5NigQ>?				MnHwTY5pcWKrdHnvckBw\iCqdX3hckBkgWOub3;4fYdmdmG\|ZT2xJIV5eHKnc4Pl[EBqdiCFT2OgZ4VtdHNuIFnDOVAhRSBzLk[4PUDPxE1w	Mnf4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2NUSyOFIoRjF3NEW0NlQzRC:jPh?=
COS	NV23R4xvTnWwY4Tpc44h[XO\|YYm=				MmC5TY5pcWKrdHnvckBw\iCqdX3hckBEV1hzIHX4dJJme3OnZDDpckBi\nKrY3HuJIdz\WWwIH3vcotmgSCFT2OgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjcnHjbIlld26rYzDhZ4llNXO2aX31cIF1\WRiUFfFNkB1emWjdHXkJFEhcHJiYnXmc5JmKGG{YXPobYRwdmmlIHHjbYQh[2ijbHzlcodmKGK7IHXufplu\SCrbX31co9ie3OjeTygTWM2OCB;IEGuOlg6KM7:TT6=	MoXXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3MkC1O\|MoRjF7NUKwOVc{RC:jPh?=
RAW264.7	NEDTVGlCdnSraX7mcIFudWG2b4L5JIF{e2G7		MUGxPEBpenN?		MYnBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW\|I3PC55IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRibnn0dolkKG:6aXTlJJBzd2S3Y4Tpc44h[W[2ZYKgNVghcHK\|IHL5JIdzcWW\|czDy[YFkfGmxbjDhcoFtgXOrczygTWM2OCB;IEGuPFQh\|ryPLh?=	NUDi[m5XRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|k1PDFpPkK0Olc6PDRzPD;hQi=>
HCA-7	MkXsR5l1d3SxeHnjbZR6KGG\|c3H5		M1;UN\|E5KGi{cx?=		M2\remN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhESS15IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxic4Xyeol3[WxiYX\0[ZIhOThiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDJizszNMi=>	NHfmeFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxO\|czOSd-MkO1NVc4OjF:L3G+
A549	M1\KbmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NGn1Sng1QCCqcoO=		MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOi5zNTFOwG0v	NFrqfXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0OlM3Pyd-Mk[zOFY{Pjd:L3G+
Escherichia coli Arctic cells	NHXwWXdHfW6ldHnvckBie3OjeR?=		NIXHT2YyPSCvaX7z		NHLkeZJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JHN1emWydH;jc4NkfXNibYX0ZY5{KFWDMUW5JIJmfGFvY3HyZo9vcWNiYX7ofYRz[XOnIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJGFz[3SrYzDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDF3IH3pcpMh[nlic4TvdJBm\CCobH;3JGNQOiCqeXTyZZNmKGG\|c3H5MEBMcSB;IEKuOFI2KM7:TT6=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzM{G5PUc,OjV7MUOxPVk9N2F-
HT-29	M2q1cmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHn2WogyQCCqcoO=		NVfLZnRiS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDDzeZJ3cX[jbDDh[pRmeiBzODDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMzFOwG0v	NW\CUJRTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVc4OjFpPkKzOVE4PzJzPD;hQi=>
J774	MVjGeY5kfGmxbjDhd5NigQ>?				NYjGd5Z4UW6qaXLpeIlwdiCxZjDDU3gyKGmwIH3veZNmKEp5N{SgZ4VtdHNiYYPz[ZN{\WRiYYOgZZJi[2irZH;ubYMh[WOrZD3pcoR2[2WmIGDHSVIhdGW4ZXzzJIJ6KHKjZHnvJIludXWwb3Hzd4F6NCCLQ{WwJF0hOy55IN88UU4>	M4fCeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUG1PFU1Lz5zN{mxOVg2PDxxYU6=
J774	MmjuSpVv[3Srb36gZZN{[Xl?		Ml7FNVUhdWmwcx?=		MkPGTY5pcWKrdHnvckBw\iCFT2ixJIlvKGG{YXPobYRwdmmlIHHjbYQue3SrbYXsZZRm\CCvb4Xz[UBLPzd2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhWEeHMjDwdo9lfWO2aX;uJIFnfGW{IEG1JI1qdnNiYomgdoFlcW:rbX31co9ie3OjeTygTWM2OCB;IEOuO{DPxE1w	NF7tR4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe1Nlk2Pyd-MUi3OVI6PTd:L3G+
J774	MlGzSpVv[3Srb36gZZN{[Xl?		MY[xOUBucW6\|		MUHJcohq[mm2aX;uJI9nKEORWD2xMY1m\GmjdHXkJHBITTJicILv[JVkfGmxbjDpckBiemGlaHnkc45q[yCjY3nkMZN1cW23bHH0[YQhdW:3c3WgTlc4PCClZXzsd{BqdmO3YnH0[YQh\m:{IEG1JI1qdnNicILpc5IhfG9iYYLhZ4hq\G:waXOgZYNq\C2laHHscIVv\2ViYomgdoFlcW:rbX31co9ie3OjeTygTWM2OCB;IEOuPFQh\|ryPLh?=	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl7MkG3Okc,OjF7OUKxO\|Y9N2F-
J774	M17mUGZ2dmO2aX;uJIF{e2G7		M1;KTFE2KG2rboO=		MXvJcohq[mm2aX;uJI9nKEORWEGgbY4hdW:3c3WgTlc4PCClZXzsd{B2e2mwZzDhdoFkcGmmb37pZ{Bi[2mmIHHzJJN2[nO2cnH0[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHBITTJicILv[JVkfGmxbjDpcoN2[mG2ZXSg[o9zKDF3IH3pcpMheHKrb4KgeI8he3Wkc4TyZZRmKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFMxKG2rboOgZpkhemGmaX;pcY12dm:jc4PhfUwhUUN3MDC9JFMvQDRizszNMi=>	M{TDV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkiwOFQ1Lz5{M{[4NFQ1PDxxYU6=
APC10.1	NF7rTJFEgXSxdH;4bYNqfHliYYPzZZk>		MlP3NVghcHK\|		NFewR2lEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBCWENzMD6xJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOnbHygd5Vzfmm4YXygZYZ1\XJiMUigbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IESuNkDPxE1w	NFGxbZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{WxO\|czOSd-MkO1NVc4OjF:L3G+
B16F10	M3XjT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NELEVZUzPCCqcoO=		M4fnO2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQkG2SlExKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0MlU3KM7:TT6=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4NkK0NEc,OjV6Nk[yOFA9N2F-
HCA-7	MUjDfZRwfG:6aXPpeJkh[XO\|YYm=				M4fyUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEORWD2yJJBwe2m2aY\lJIh2dWGwIFjDRU04KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGK7IFPlcIxVcXSncj25OkBCWXWnb4XzJIF{e2G7LDDJR\|UxKD1iND65JO69VS5?	M2X1Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm1O\|g4Lz5{NEK5OVc5PzxxYU6=
SH-SY5Y	MXnBcpRqdmW3cn;0c5hq[2m2eTDhd5NigQ>?		NEHJSFY4OiCqcoO=		MWTBcpRqdmW3cn;0c5hq[2m2eTDpckBpfW2jbjDTTE1UYTW\IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gbJVu[W5iVFjQNUBk\WyuIIP1dIVzdmG2YX70MYlv\HWlZXSgZ5l1d3SxeHnjbZR6KGOxbYDveY5lKHC{ZYTy[YF1\WRiMkSgeI8hPDhiaILzJJRwKFSKUEGgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJI9nKHO3cHXycoF1[W62IHHk[Il1cW:wLDDJR\|UxKD1iNTFOwG0v	MmfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzM{i3O\|AoRjJyMUO4O\|cxRC:jPh?=
THP1	NV7LTVBPVmW3cn;wdo91\WO2aY\lJIF{e2G7		MXu3NkBpenN?		M1zJfG5mfXKxcILveIVkfGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFzQV{BidmRiSV\OMYdidW2jLYP0bY12dGG2ZXSgcoV2em:2b4jpckBxem:mdXP0bY9vKGmwIHj1cYFvKFSKUEGgZ4VtdCCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFSKUEGgZ4VtdCC\|ZXPy[ZRqd25vaX7keYNm\CC2b4jpZ4l1gSC2bzDoeY1idiCVSD3TXVV[KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC1JO69VS5?	MnrkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4MEm1PFkoRjJyNkC5OVg6RC:jPh?=
U-937	M1L3[WZ2dmO2aX;uJIF{e2G7				M3riNmlvcGmkaYTpc44hd2ZiUILvd5Ri\2yjbnTpckBIN0hic4nueIhie2ViMTDpckBWNTl\|NzDj[YxteyCocn;tJIh2dWGwIHjpd5Rqd2O7dHnjJIx6dXCqb33hMEBKSzVyIE2gOU4yKM7:TT6=	MkTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF2NkK5O\|YoRjFzNE[yPVc3RC:jPh?=
U-937	NU\PdYNGTnWwY4Tpc44h[XO\|YYm=				M4\FcGlvKH[rdILvJIlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQdo9{fGGpbHHu[IlvKEdxSDDzfY51cGG\|ZTCxJEhEV1hvMTmgbY4hXS17M{egZ4VtdHNuIFnDOVAhRSB3LkGg{txONg>?	NHSzWI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMki3O\|U5PCd-MUK4O\|c2QDR:L3G+
J774	NET4eZpHfW6ldHnvckBie3OjeR?=				NXXuS5BTUW5idnn0do8hcW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KFC{b4P0ZYdt[W6maX6gS{9JKHO7boToZZNmKDFiaX6gcZVzcW6nIFq3O\|Qh[2WubIOsJGlEPTBiPTC1MlEh\|ryPLh?=	M1izUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OEW3NVQ6Lz5zNUi1O\|E1QTxxYU6=
J774	NFm0TlRHfW6ldHnvckBie3OjeR?=				MlvlTY5pcWKrdHnvckBw\iCFT2ixMYRmeGWwZHXueEBRT0V{IIDyc4R2[3Srb36gbY4hVFCVLYP0bY12dGG2ZXSgcY92e2ViSke3OEBk\WyuczDifUBTUUFuIFnDOVAhRSB3LkGg{txONg>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTl3N{mzNUc,OTl7NUe5N\|E9N2F-
HT-29	M1zNNGN6fG:2b4jpZ4l1gSCjc4PhfS=>				MUnDfZRwfG:6aXPpeJkh[WejaX7zeEBEV1hvMjDwc5NqfGm4ZTDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBjgSCFZXzsWIl1\XJvOU[gRXF2\W:3czDhd5NigSxiSVO1NEA:KDVwNzFOwG0v	NHSzd4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5OVc5Pyd-MkSyPVU4QDd:L3G+
MCF7	NVX1RXZCSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		Ml\ENlQhcHK\|		MlfxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3Lkm0JO69VS5?	NY\PflY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlYzPDBpPkK1PFY3OjRyPD;hQi=>
APC10.1	Mn;FSpVv[3Srb36gZZN{[Xl?		Mn72NVghcHK\|		MWLJcohq[mm2aX;uJI9nKGi7YXz1do9v[W5vaX7keYNm\CCFRES0JIFvfGmpZX6geoFzcWGwdDDlfI9vKDZiYXP0bZZqfHliaX6gcY92e2ViQWDDNVAvOSClZXzsd{BmgHC{ZYPzbY5oKEijc{KgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEB{fXK4aY\hcEBi\nSncjCxPEBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gOkDPxE1w	NVz2O2NVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVc4OjFpPkKzOVE4PzJzPD;hQi=>
MCF7	NXPUPHpmSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEnqUmI1QCCqcoO=		MkXBRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDZwOEig{txONg>?	M4rTN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{S2N\|Y4Lz5{NkO0OlM3PzxxYU6=
SW480	NWLhbndCS3m2b4TvfIlkcXS7IHHzd4F6				M2\zZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEORWD2yJI5m\2G2aY\lJIh2dWGwIGPXOFgxKGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGK7IFPlcIxVcXSncj25OkBCWXWnb4XzJIF{e2G7LDDJR\|UxKD1iNj65JO69VS5?	M2TJXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm1O\|g4Lz5{NEK5OVc5PzxxYU6=
HeLa	Mo\4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mm\6NlQhcHK\|		NYThdpU6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC3MlM2KM7:TT6=	M2\sbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OE[2NlQxLz5{NUi2OlI1ODxxYU6=
HeLa	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmLYOFghcHK\|		MkHxRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZVzhJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDdwNUWg{txONg>?	M3rtcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{S2N\|Y4Lz5{NkO0OlM3PzxxYU6=
HeLa	MVfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHnGdpQzPCCqcoO=		NEnJOpRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEeuO\|kh\|ryPLh?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2OUOzNUc,Ojd\|NEmzN\|E9N2F-
HepG2	NGC0cpJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3HTRVI1KGi{cx?=		M2fVUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEGwMlA{KM7:TT6=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2OUOzNUc,Ojd\|NEmzN\|E9N2F-
APC10.1	M1LGRmN6fG:2b4jpZ4l1gSCjc4PhfS=>				NXLteHpLS3m2b4TvfIlkcXS7IHHnZYlve3RiQ1;YMVIheG:\|aYTpeoUhdW:3c3WgRXBEOTBwMTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BJSVNvMjDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBjgSCFZXzsWIl1\XJvOU[gRXF2\W:3czDhd5NigSxiSVO1NEA:KDF\|LkSg{txONg>?	M4rlR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm1O\|g4Lz5{NEK5OVc5PzxxYU6=
CHO	MVHGeY5kfGmxbjDhd5NigQ>?				MWLJcohq[mm2aX;uJI9nKEORWEGg[ZhxemW\|c3XkJIlvKEOKTzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGG{YXPobYRwdmmlIHHjbYQue3SrbYXsZZRm\CCSR1WyJJBzd2S3Y4Tpc44h[nliZX76fY1mKGmvbYXuc4F{e2G7LDDJR\|UxKD1iMUOuOUDPxE1w	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTV4NkK5NEc,OTV3Nk[yPVA9N2F-
B16F10	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MkO3NlQhcHK\|		MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEJzNl[xNEBk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMUSuN\|Yh\|ryPLh?=	Mof5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NEmzN\|EoRjJ5M{S5N\|MyRC:jPh?=
A549	M1v3XmFvfGm2dX3vdkBie3OjeR?=		M1fIPFQ5KGi{cx?=		M3rp[2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG1MlYh\|ryPLh?=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3M{e0NUc,OjN\|NUO3OFE9N2F-
A549	NXP5NI84SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NE[0dVEzPCCqcoO=		MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF3Lk[0JO69VS5?	NHn4PFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O0PVM{OSd-MkezOFk{OzF:L3G+
HeLa	Ml3yRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVG0PEBpenN?		M{DI[GFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMUWuOlkh\|ryPLh?=	MlOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{G2OVIoRjNyMEOxOlUzRC:jPh?=
A549	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEDG[oU1QCCqcoO=		Moj3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzNj6wPEDPxE1w	NYLG[FhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|E3PTJpPkOwNFMyPjV{PD;hQi=>
NCI60	NV;mN49HT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVu0PEBpenN?		M4LOT2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG5EUTZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDHTVUxKD1iMUeuOUDPxE1w	MmDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|OEe4NVUoRjJyM{i3PFE2RC:jPh?=
HCA-7	M1jmbWZ2dmO2aX;uJIF{e2G7		NYK0dZNuOThiaILz		NV\mTYlOUW6qaXLpeIlwdiCxZjDofYFtfXKxbnHuMYlv\HWlZXSgR2Q1PCCjboTp[4VvKH[jcnnhcpQh\XixbjC2JIFkfGm4aYT5JIlvKGi3bXHuJGhESS15IHPlcIx{KGW6cILld5NqdmdiSHHzNkBie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKHO3co\peoFtKGGodHXyJFE5KGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAyPy53IN88UU4>	MoHpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUe3NlEoRjJ\|NUG3O\|IyRC:jPh?=
HT-29	NFiwW4VHfW6ldHnvckBie3OjeR?=		NW[xfIRJOThiaILz		NVX6bpY1UW6qaXLpeIlwdiCxZjDofYFtfXKxbnHuMYlv\HWlZXSgR2Q1PCCjboTp[4VvKH[jcnnhcpQh\XixbjC2JIFkfGm4aYT5JIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGW6cILld5NqdmdiSHHzNkBie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKHO3co\peoFtKGGodHXyJFE5KGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAyQC5\|IN88UU4>	NV\TRYZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVc4OjFpPkKzOVE4PzJzPD;hQi=>
platelet	M1XTXGZ2dmO2aX;uJIF{e2G7				NX7helBjUW6qaXLpeI9zgSCnZn\lZ5Qhd25icILv[JVkfGmxbjDv[kBkgWOub3;4fYdmdmG\|ZT2xJEhEV1hvMTmgeIhzd22kb4jhcoUhSjJiKGTYRlIqKGmwIHj1cYFvKHCuYYTlcIV1KGOnbHzzMEBKSzVyIE2gNVkh\|ryPLh?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODh{MUexOkc,OTB6MkG3NVY9N2F-
B16F10	MmrKRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUW0PEBpenN?		NXTBRYxJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCNVZHOTBiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE6NjF3IN88UU4>	NWDC[Yp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN\|E3PTJpPkOwNFMyPjV{PD;hQi=>
MDA231	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				M17Xe2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBNlMyKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJ{Lke5JO69VS5?	NYK1UJp[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNVY5PDhpPkOwNlE3QDR6PD;hQi=>
MCF7	NHjKSm1CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NXLjUXY2PDhiaILz		M{jxPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMk[uO\|gh\|ryPLh?=	Mk\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{G2OVIoRjNyMEOxOlUzRC:jPh?=
HCT116	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				M{fyb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJ7LkW0JO69VS5?	NEfxT5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKxOlg1QCd-M{CyNVY5PDh:L3G+
MCF7	M3LLeWFvfGmycn;sbYZmemG2aY\lJIF{e2G7				MYjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN\|EvOjhizszNMi=>	NEPDN5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEKxOlg1QCd-M{CyNVY5PDh:L3G+
LNCAP	MnmyR5l1d3SxeHnjbZR6KGG\|c3H5		NYK4c3BvPzJiaILz		MonqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUG5ESVBiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN\|IvPiEQvF2u	MlW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyNUe0NFcoRjJ6MEW3OFA4RC:jPh?=
BL21(DE3)	NYnrd3JkTnWwY4Tpc44h[XO\|YYm=		NW\V[VRSOTVibXnudy=>		MXXJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiTXHsZZN{\XqrYTDncI9jd3OjIFHUR2MhQTZ6MEevR2JUKDd7Nk[gUWcuS0FiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSiGRUOpJINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMUWgcYlveyCvZXHzeZJm\CCob4KgNVAhfG9iMUCwJJNm[yCkeTDzeI9xeGWmLX\sc5chdWW2aH;kMEBMcSB;IEO0Mlgh\|ryPLh?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR{NEKzPUc,OjJ2MkSyN\|k9N2F-
HeLa	NXrUTJp3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				NGrqWpFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOzZwMEig{txONg>?	NUH3OnNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNVY5PDhpPkOwNlE3QDR6PD;hQi=>
MDA-MB-231	MorKR5l1d3SxeHnjbZR6KGG\|c3H5		NF7JdVA1QCCqcoO=		M1fuemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IESwJO69VS5?	NEXzWI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke4NFk3OSd-MkK3PFA6PjF:L3G+
MCF7	M1e3PGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3LEflQ5KGi{cx?=		NHLHZ3RCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBkd2yxcnnt[ZRzcWNiYYPzZZktKEmFNUCgQUA1OC56IN88UU4>	NEfocVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCwNFk1QCd-MkKwNFA6PDh:L3G+
MCF7	MYfBcpRqfHWvb4KgZZN{[Xl?		NInvXYg1QCCqcoO=		M2LSR2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IESwMlgh\|ryPLh?=	M1rwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{WzO\|QyLz5{M{O1N\|c1OTxxYU6=
Caco2	MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				Mn\6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFYXPvNkBk\WyuczDifUBOXFRiYYPzZZktKEmFNUCgQUA1Oi55NDFOwG0v	NVrO[FVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNVY5PDhpPkOwNlE3QDR6PD;hQi=>
HCT116	M3rhTmFvfGmlYX7j[ZIh[XO\|YYm=		NHu3NWc4OiCqcoO=		MX3BcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0N{4{KM7:TT6=	M3iye\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNke4PVcyLz5{MU[3PFk4OTxxYU6=
L1210	NHzNZ\|BEgXSxdH;4bYNqfHliYYPzZZk>		NWLBeGoyPzJiaILz		MmnlR5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgUFEzOTBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQ1KM7:TT6=	NXrJVWRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OVE{QTdpPkKwOFUyOzl5PD;hQi=>
HT-29	M13NWGN6fG:2b4jpZ4l1gSCjc4PhfS=>				M3X6bGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OCB;IES1MlUh\|ryPLh?=	M4fYeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEC0NVk4Lz5{MEiwOFE6PzxxYU6=
PC3	NFnBZlFCdnSrY3HuZ4VzKGG\|c3H5				MmPZRY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczygS2k2OCB;IES3JO69VS5?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ4MkOwPUc,OTh{NkKzNFk9N2F-
PC3	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYK3NkBpenN?		MoXsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDhcoRzd2enbj3pcoRmeGWwZHXueEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEB1\XO2LDDJR\|UxKD1iNEeg{txONg>?	NYPpOHhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1OlYzQTBpPkG1OVY3OjlyPD;hQi=>
PC3	M1n4fGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVi3NkBpenN?		Mlv4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDR6IN88UU4>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl\|N{m3Nkc,OTd7M{e5O\|I9N2F-
PC3	NY\IOIxUTnWwY4Tpc44h[XO\|YYm=		NWmyWphIOiCqcoO=		MYTJcohq[mm2aX;uJI9nKFCGS{GtcYVlcWG2ZXSgRYt1KGGldHn2ZZRqd25iaX6gbJVu[W5iUFOzJINmdGy\|IHHmeIVzKDJiaILzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZMtKEmFNUCgQUA1QCEQvF2u	NFT0Wpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{ezOVI5OSd-MkO3N\|UzQDF:L3G+
PC3	NX7VbllzS3m2b4TvfIlkcXS7IHHzd4F6		MWe3NkBpenN?		NEXp[ItEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQ5NjVizszNMi=>	NXPWR3RJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OVE{QTdpPkKwOFUyOzl5PD;hQi=>
MCF7	NHvzSGhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmTEO\|IhcHK\|		MlPrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB2OT62OkDPxE1w	M2Hu[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUmxOVAzLz5{OUG5NVUxOjxxYU6=
A549	NYrTUG9iTnWwY4Tpc44h[XO\|YYm=				NV\iVGQxUW6qaXLpeIlwdiCxZjDDU3gzNWSncHXu[IVvfCCSR1WyJJBzd2S3Y4Tpc44hcW5iSVyxRkB{fGmvdXzheIVlKGi3bXHuJGE2PDliY3XscJMhcW5icILld4Vv[2Vib3[gZZJi[2irZH;ubYMh[WOrZB?=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR7OEG1NEc,OTh2OUixOVA9N2F-
A549	MWTGeY5kfGmxbjDhd5NigQ>?				MXvJcohq[mm2aX;uJI9nKEORWEKt[IVx\W6mZX70JHBITTJicILv[JVkfGmxbjDpckBKVDGEIIP0bY12dGG2ZXSgbJVu[W5iQUW0PUBk\Wyucx?=	NWTRTXE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0PVgyPTBpPkG4OFk5OTVyPD;hQi=>
A549	NHH3d2xHfW6ldHnvckBie3OjeR?=	NVTiSGpVPSC3TR?=			M2[wbWlvcGmkaYTpc44hd2ZibWDHSXMyKGmwIHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCLTD2xMYJmfGFvaX7keYNm\CCSR1WyJIZwem2jdHnvckBifCB3IIXNJIJ6KGOnbHytbY51[WO2IHHzd4F6	MomwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlyNUO3OVEoRjF7MEWzO\|UyRC:jPh?=
A549	M4jMcWZ2dmO2aX;uJIF{e2G7	MonnOUB2VQ>?	MkD2NVAhdWmwcx?=		M4rhR2lvcGmkaYTpc44hd2ZibWDHSXMyKGmwIFnMNU1j\XSjIHnu[JVk\WRiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDQS2UzKHC{b3T1Z5Rqd25iYYSgOUB2VSCycnXpcoN2[mG2ZXSg[o9zKDFyIH3pcpM>	NVToWIc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4PFQxOTFpPkG5PFg1ODFzPD;hQi=>
PANC1	MVXGeY5kfGmxbjDhd5NigQ>?	NEPyRWkzPSC2bzC1NEBO	NVjpU3hPOzBibXnudy=>		MnTrTY5pcWKrdHnvckBw\iCLTD22MYlv\HWlZXSgV3RCXDNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKFCDTlOxJINmdGy\|IHH0JFI2KHSxIEWwJG0heHKndILlZZRm\CB{IHjyd{BxemmxcjD0c{BKVC14IHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB\|MDDtbY5{	Mny2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4N{i5O\|EoRjJzNke4PVcyRC:jPh?=
HT29	MnLQSpVv[3Srb36gZZN{[Xl?	NWnOV2NHOTBidV2=			MYXJcohq[mm2aX;uJI9nKGi7YXz1do9v[W5vaX7keYNm\CCFRES0JIFvfGmpZX6geoFzcWGwdDDlfI9vKDZiYXP0bZZqfHliaX6gbJVu[W5iSGSyPUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiB3LVzPXEBmgHC{ZYPzbY9vKGG2IEGwJJVO	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzVzN{eyNUc,OjN3MUe3NlE9N2F-
HT29	NFzRUpBHfW6ldHnvckBie3OjeR?=	MkT3NVAhfU1?			MXzJcohq[mm2aX;uJI9nKGi7YXz1do9v[W5vaX7keYNm\CCFRES0JIFvfGmpZX6geoFzcWGwdDDlfI9vKDZiYXP0bZZqfHliaX6gbJVu[W5iSGSyPUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCFT2itNkBmgHC{ZYPzbY9vKGG2IEGwJJVO	M13aSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG3O\|IyLz5{M{WxO\|czOTxxYU6=
HCA-7	MX7GeY5kfGmxbjDhd5NigQ>?	MYC1JJVO	NWf0T406OjRiaILz		NYT1U5J3UW6qaXLpeIlwdiCxZjDofYFtfXKxbnHuMYlv\HWlZXSgR2Q1PHZ4IHnuJIh2dWGwIFjDRU04KGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigTIF{OmOGTlGgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhPS2OT2igdJJwfGWrbjDlfJBz\XO\|aX;uJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXN?	M1;aWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm1O\|g4Lz5{NEK5OVc5PzxxYU6=
HCA-7	MmXZSpVv[3Srb36gZZN{[Xl?	MmjFOUB2VQ>?	NYjBcWFkOjRiaILz		MmSyTY5pcWKrdHnvckBw\iCqeXHseZJwdmGwLXnu[JVk\WRiQ1S0OJY3KGmwIHj1cYFvKEiFQT23JINmdGy\|IITyZY5{\mWldHXkJJdqfGhiSHHzNoNFVkFiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gR29ZNTJicILveIVqdiCneIDy[ZN{cW:wIHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	Mn:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUW3PFcoRjJ2Mkm1O\|g4RC:jPh?=
HCA-7	NV7YNW9zTnWwY4Tpc44h[XO\|YYm=	NXLtXWp4PSC3TR?=	NX[0[\|VJOjRiaILz		NWT6PXlXUW6qaXLpeIlwdiCxZjDofYFtfXKxbnHuMYlv\HWlZXSgR2Q1PHZ4IHnuJIh2dWGwIFjDRU04KGOnbHzzJJRz[W6\|ZnXjeIVlKHerdHigTIF{OmOGTlGgZZN{\XO\|ZXSgZZMh\G:5boLl[5Vt[XSrb36gc4YhS0:[LUGgdJJwfGWrbjDlfJBz\XO\|aX;uJIF1KDVidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdiYX7hcJl{cXN?	NX63dIVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVU4QDdpPkK0Nlk2Pzh5PD;hQi=>
HeLa	MnPNSpVv[3Srb36gZZN{[Xl?	NHjiN4MyODBidV2=	MlnPNlQhcHK\|		MX7Jcohq[mm2aX;uJI9nKG2SR1XTMVEhcW5iaIXtZY4hUGWOYTDj[YxteyC3c3nu[{BRT0h{IHHzJJN2[nO2cnH0[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNNTGkZYThM3RPTmGucHjhMZN1cW23bHH0[YQhWEeHMjDwdo9lfWO2aX;uJIF1KDFyMDD1UUBi\nSncjCyOEBpenNiYomgUGMuVVNxTWOgZY5idHm\|aYO=	NUHWUFdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFM4OzlpPkK0NVg{PzN7PD;hQi=>
HeLa	M1G2fGZ2dmO2aX;uJIF{e2G7	M3HYcFAvOSC3TR?=	M4DzeVI1KGi{cx?=		Mm\1TY5pcWKrdHnvckBw\iCSR1WyJJNm[3KndHnvckBqdiCqdX3hckBJ\UyjIHPlcIx{KGG2IECuNUB2VSCjZoTldkAzPCCqcoOgZpkhTUmDIH3vco9kdG:wYXygZZN{[Xl?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2OUOzNUc,Ojd\|NEmzN\|E9N2F-
Saos-2	M1\NNZFJXFNiYYPzZZk>				NHv4do1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	NUD3WXdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RAW264.7	MXXBcpRqcW6obHHtcYF1d3K7IHHzd4F6	MUKyNEB2VQ>?	M37lcFIhcHK\|		MYjBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHHnZYlve3RibX;1d4UhWkGZMk[0Mlch[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMhcW6mdXPl[EBkd3hvMjDlfJBz\XO\|aX;uJIF1KDJyIIXNJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgUHBUKGOqYXzs[Y5o\SCvZXHzeZJm\CCjZoTldkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2IH3leIhw\A>?	Mm\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMEC3PVkoRjJ7MUCwO\|k6RC:jPh?=
RAW264.7	NU\jdoN2SW62aXnu[oxidW2jdH;yfUBie3OjeR?=	NVThUYg4OjBidV2=	Mk\JNkBpenN?		NGPVc2ZCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViUlHXNlY1NjdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNiaX7keYNm\CCrTl;TJIV5eHKnc4Ppc44h[XRiMkCgeW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBNWFNiY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m	Mnv5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMEC3PVkoRjJ7MUCwO\|k6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Water	Insoluble
	Ethanol	'33 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib (SC 58635) SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02876094	Terminated	Drug: celecoxib	Spinal Muscular Atrophy (SMA)	Hugh McMillan\|Families of Spinal Muscular Atrophy\|Gwendolyn Strong Foundation\|Children''s Hospital of Eastern Ontario	January 29 2019	Phase 2
NCT03185871	Withdrawn	Drug: Celecoxib	Breast Carcinoma	University of Wisconsin Madison\|National Cancer Institute (NCI)	September 20 2017	Phase 2
NCT02413203	Completed	Drug: Celecoxib\|Drug: Placebo	Healthy	University of Pennsylvania\|Eli Lilly and Company	March 2015	Not Applicable
NCT03305068	Unknown status	Drug: Celecoxib	Reverse or Primary Total Shoulder\|Rotator Cuff- Full Thickness- Repair	St. Louis Joint Replacement Institute	February 2014	Phase 4
NCT02429427	Completed	Drug: Celecoxib\|Other: Placebo	Breast Cancer	Imperial College London\|Institute of Cancer Research United Kingdom	December 2005	Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Xanthohumol inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. Xanthohumol is also a potent antiviral agent against a series of DNA and RNA viruses. Xanthohumol induces growth inhibition and apoptosis in cancer cells. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
Nirogacestat (PF-03084014) ^New

Nirogacestat (PF-03084014, PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Nirogacestat (PF-03084014, PF-3084014) induces apoptosis. Phase 2.
Indomethacin (NSC-77541)

Indomethacin (NSC-77541, Indometacin) is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam (Chlortenoxicam) is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin (NSC 27223)

Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Rofecoxib

Rofecoxib (MK-0966) is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen (NSC 256857)

Ibuprofen (NSC 256857, Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type

Celecoxib (SC 58635)